In this article, we will discuss Larotrectinib (Dosage Overview). So, let’s get started.
Larotrectinib is indicated for the treatment of adult and pediatric patients with solid tumors that:
• have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired
• are metastatic or where surgical resection is likely to result in severe morbidity, and
• have no satisfactory alternative treatments or that have progressed following treatment.
Select patients for treatment with Larotrectinib based on the presence of a NTRK gene fusion in tumor specimens. An FDA-approved test for the detection of NTRK
gene fusion is not currently available.
Recommended Dosage in Adult and Pediatric Patients with Body Surface Area of at Least 1.0 Meter-Squared.
The recommended dosage of Larotrectinib is 100 mg orally twice daily, with or without food, until disease progression or until unacceptable toxicity.
Recommended Dosage in Pediatric Patients with Body Surface Area Less Than 1.0 Meter-Squared.
The recommended dosage of Larotrectinib is 100 mg/m2 orally twice daily, with or without food, until disease progression or until unacceptable toxicity.